Study S000841

A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)

ClinicalTrials.gov record

Registration

Registration: NCT01515553
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 22
Start: 2007-01
Primary completion: 2007-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2006-004283-31

Registered primary outcomes

Area under the curve (0-t) []
Cmax, maximum concentration []

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.